肝脏
肝髒
간장
CHINESE HEPATOLOGY
2015年
4期
281-284
,共4页
奥沙利铂%肝动脉栓塞化疗%原发性肝癌%临床疗效
奧沙利鉑%肝動脈栓塞化療%原髮性肝癌%臨床療效
오사리박%간동맥전새화료%원발성간암%림상료효
Oxaliplatin%TACE%Hepatocellular carcinoma%Clinical efficacy
目的：分析奥沙利铂联合肝动脉化疗栓塞术（TACE）治疗原发性肝癌的临床疗效。方法选取58例原发性肝癌患者，随机分为2组，对照组29例单独使用 TACE 治疗；观察组29例奥沙利铂联合 TACE 进行治疗，检测两组患者治疗前和治疗2周后血清中 TNF-α、AFP、WBC、CEA 水平及肿瘤直径的变化，并记录治疗总有效率和不良反应发生情况，统计患者的生活质量和满意度。结果治疗后观察组 TNF-α、AFP、CEA 水平、肿瘤直径分别为（11.25±1.14）μg／L、（289.97±10.32）μg／L、（100.49±11.43）μg／L、（3.87±0.79）cm，各指标均减少，白细胞数目（5.08±1.31）×109个，几乎没有变化。与对照组比较，差异有统计学意义（P ＜0.05），且观察者患者治疗总有效率、生活质量、患者满意度均比对照组高，不良反应发生率较对照组偏低，差异有统计学意义（P ＜0.05）。结论奥沙利铂联合 TACE 可提高患者治疗总有效率、生活质量和满意度，降低不良反应发生率，疗效确切，安全有效，值得在临床推广。
目的：分析奧沙利鉑聯閤肝動脈化療栓塞術（TACE）治療原髮性肝癌的臨床療效。方法選取58例原髮性肝癌患者，隨機分為2組，對照組29例單獨使用 TACE 治療；觀察組29例奧沙利鉑聯閤 TACE 進行治療，檢測兩組患者治療前和治療2週後血清中 TNF-α、AFP、WBC、CEA 水平及腫瘤直徑的變化，併記錄治療總有效率和不良反應髮生情況，統計患者的生活質量和滿意度。結果治療後觀察組 TNF-α、AFP、CEA 水平、腫瘤直徑分彆為（11.25±1.14）μg／L、（289.97±10.32）μg／L、（100.49±11.43）μg／L、（3.87±0.79）cm，各指標均減少，白細胞數目（5.08±1.31）×109箇，幾乎沒有變化。與對照組比較，差異有統計學意義（P ＜0.05），且觀察者患者治療總有效率、生活質量、患者滿意度均比對照組高，不良反應髮生率較對照組偏低，差異有統計學意義（P ＜0.05）。結論奧沙利鉑聯閤 TACE 可提高患者治療總有效率、生活質量和滿意度，降低不良反應髮生率，療效確切，安全有效，值得在臨床推廣。
목적：분석오사리박연합간동맥화료전새술（TACE）치료원발성간암적림상료효。방법선취58례원발성간암환자，수궤분위2조，대조조29례단독사용 TACE 치료；관찰조29례오사리박연합 TACE 진행치료，검측량조환자치료전화치료2주후혈청중 TNF-α、AFP、WBC、CEA 수평급종류직경적변화，병기록치료총유효솔화불량반응발생정황，통계환자적생활질량화만의도。결과치료후관찰조 TNF-α、AFP、CEA 수평、종류직경분별위（11.25±1.14）μg／L、（289.97±10.32）μg／L、（100.49±11.43）μg／L、（3.87±0.79）cm，각지표균감소，백세포수목（5.08±1.31）×109개，궤호몰유변화。여대조조비교，차이유통계학의의（P ＜0.05），차관찰자환자치료총유효솔、생활질량、환자만의도균비대조조고，불량반응발생솔교대조조편저，차이유통계학의의（P ＜0.05）。결론오사리박연합 TACE 가제고환자치료총유효솔、생활질량화만의도，강저불량반응발생솔，료효학절，안전유효，치득재림상추엄。
Objective To analyze clinical efficacy of oxaliplatin combined with transcatheter arterial chemoembolization (TACE )in treatment of primary liver cancer. Methods Fifty-eight patients with hepatocellular carcinoma from March 2011 to September 2014 in our hospital were enrolled and randomly divided into two groups.Twenty-nine patients of control group were treated with TACE,while patients of observation group were treated with oxaliplatin combined with TACE.Serum tumor necrosis factor-α (TNF-α),alpha fetal protein (AFP),white blood cell (WBC), carcino embryonic antigen (CEA)level and tumor diameter were detected at baseline and after two weeks of treatment. Total effective rate and adverse reactions after chemotherapy were recorded.In addition,patient's quality of life and satisfaction were analyzed.Results TNF-α,AFP,CEA level and tumor size of observation group were decreased after treatment,which showed significant difference with those of control group (P <0.01 ).However,WBC had not showed marked change after treatment between two groups.Moreover,total effective rate,quality of life,patient satisfaction of observation group were higher than those of control group,and incidence of adverse reactions in observation group was much lower than that in control group.The differences were statistically significant (P <0.05 ).Conclusion Oxaliplatin combined with TACE could improve total effective rate,patients'quality of life,patient satisfaction,and reduce incidence of adverse reactions,which showed safety and effectiveness.The therapeutic schedule is worth of being popularized in clinical application.
